BioScrip Inc (NASDAQ:BIOS) shares fell 15.6% on Thursday following a dissappointing earnings announcement. The company traded as low as $2.44 and last traded at $2.59. 5,172,454 shares traded hands during mid-day trading, an increase of 453% from the average session volume of 934,677 shares. The stock had previously closed at $3.07.
The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.07). The business had revenue of $182.50 million for the quarter, compared to analysts’ expectations of $171.35 million. BioScrip’s revenue for the quarter was down 24.0% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.06) earnings per share.
A number of research firms have commented on BIOS. BidaskClub downgraded shares of BioScrip from a “buy” rating to a “hold” rating in a report on Friday. SunTrust Banks reaffirmed a “buy” rating and issued a $3.25 price objective on shares of BioScrip in a report on Thursday. Craig Hallum reaffirmed a “buy” rating and issued a $3.50 price objective on shares of BioScrip in a report on Thursday. Zacks Investment Research raised shares of BioScrip from a “sell” rating to a “hold” rating in a report on Wednesday, January 10th. Finally, ValuEngine upgraded BioScrip from a “sell” rating to a “hold” rating in a research note on Thursday, November 30th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. BioScrip presently has an average rating of “Buy” and a consensus target price of $3.45.
The company has a debt-to-equity ratio of -6.11, a quick ratio of 1.60 and a current ratio of 1.91.
WARNING: “BioScrip (BIOS) Shares Down 15.6% on Disappointing Earnings” was published by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States and international copyright laws. The original version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3253988/bioscrip-bios-shares-down-15-6-on-disappointing-earnings.html.
BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.